This Defense Health Agency Project Grant award of $1,225,878.00 to Baylor College of Medicine, granted under the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420), is investigating the use of nebivolol, a beta-blocker medication, as a potential treatment for triple-negative breast cancer. The research project, which runs from January 1, 2024 to December 31, 2026, aims to advance scientific understanding and develop new treatment options for this aggressive form of breast cancer that disproportionately affects military service members and veterans. As a leading academic medical center, Baylor College of Medicine has extensive experience conducting biomedical research and providing specialized medical services to federal agencies, including the Department of Veterans Affairs.
Generated 8/13/24, 8:44 AM